Scientific and Clinical Directors

Lilach Chen, Director of INspire Technology

Lilach serves as the Director of INspire Technology, Biond’s intracellular delivery platform, since 2024. Prior to that, Lilach was a senior scientist at Biond, leading the multidisciplinary research and development of INspire platform. Lilach also served as project manager at the R&D department at Tambour company, leading various projects from development to manufacturing and marketing stages. Lilach was project manager at Protalix Biotherapeutics, driving the development of chemically modified therapeutic proteins across various projects. Lilach holds a Ph.D. degree in organic chemistry from the Schulich faculty of chemistry at the Technion

Natalia Ashtamker, Director of Clinical Development

Natalia serves as Biond’s Director of Clinical Development since April 2023. She has over 15 years of drug development experience and treatment of neurological diseases and other diseases. Natalia joined Biond from BOL Pharma where she was Head of Clinical Development, leading pharmaceutical development of cannabinoid-based drug products for various indications. Prior to BOL Pharma, she served as the Medical Director at Intec Pharma responsible for leading all their clinical phase projects. Prior to joining Intec Pharma, she was the Director and Clinical Program Leader at Teva Pharmaceuticals for COPAXONE®, a medication used to treat multiple sclerosis (MS),. Natalia earned her M.D from the Faculty of Medicine, St. Petersburg Pavlov Medical University, Russia

Tali Kizhner, Director of Intracellular Programs

Tali serves as Biond’s Director of Intracellular Programs since 2021. She has over 15 years of diverse R&D and CMC experience in development of therapeutic proteins and dietary supplements. Tali joined Biond from International Fragrance and Flavors (IFF), where she was R&D Director, leading local and global activities in the field of dietary supplements and functional foods. Prior to IFF, at Protalix Biotherapeutics Tali played a pivotal role in research and development of several biologics, including approved by EMEA and FDA pegunigalsidase alfa for Fabry disease. Tali holds a Ph.D. in Biotechnology and Food Engineering from the Technion – Israel Institute of Technology